Emergent BioSolutions Inc. (EBS)’s Financial Results Comparing With Kura Oncology Inc. (NASDAQ:KURA)

We will be contrasting the differences between Emergent BioSolutions Inc. (NYSE:EBS) and Kura Oncology Inc. (NASDAQ:KURA) as far as analyst recommendations, profitability, risk, dividends, institutional ownership, earnings and valuation are concerned. The two businesses are rivals in the Biotechnology industry.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Emergent BioSolutions Inc. 855.20M 2.61 41.60M 0.73 62.31
Kura Oncology Inc. N/A 0.00 59.78M -1.63 0.00

Table 1 shows the top-line revenue, earnings per share (EPS) and valuation for Emergent BioSolutions Inc. and Kura Oncology Inc.

Profitability

Table 2 represents Emergent BioSolutions Inc. (NYSE:EBS) and Kura Oncology Inc. (NASDAQ:KURA)’s return on equity, net margins and return on assets.

Net Margins Return on Equity Return on Assets
Emergent BioSolutions Inc. 4.86% 4.3% 2.5%
Kura Oncology Inc. 0.00% -40% -35.5%

Volatility and Risk

A beta of 1.39 shows that Emergent BioSolutions Inc. is 39.00% more volatile than S&P 500. Kura Oncology Inc.’s 165.00% more volatile than S&P 500 which is a result of the 2.65 beta.

Liquidity

Emergent BioSolutions Inc. has a Current Ratio of 2.1 and a Quick Ratio of 1.3. Competitively, Kura Oncology Inc.’s Current Ratio is 13.8 and has 13.8 Quick Ratio. Kura Oncology Inc.’s better ability to pay short and long-term obligations than Emergent BioSolutions Inc.

Analyst Recommendations

Ratings and Recommendations for Emergent BioSolutions Inc. and Kura Oncology Inc. can be find in next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Emergent BioSolutions Inc. 0 2 2 2.50
Kura Oncology Inc. 0 0 0 0.00

Emergent BioSolutions Inc.’s upside potential currently stands at 60.29% and an $69.5 consensus target price.

Institutional and Insider Ownership

Roughly 85% of Emergent BioSolutions Inc. shares are held by institutional investors while 84.8% of Kura Oncology Inc. are owned by institutional investors. Insiders held roughly 3.8% of Emergent BioSolutions Inc.’s shares. On the other hand, insiders held about 11.6% of Kura Oncology Inc.’s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Emergent BioSolutions Inc. -5.12% -14.46% -31.1% -33.02% -11.29% -23.68%
Kura Oncology Inc. -5.07% 8.34% 11.88% 34.28% -5.29% 14.67%

For the past year Emergent BioSolutions Inc. had bearish trend while Kura Oncology Inc. had bullish trend.

Summary

Emergent BioSolutions Inc. beats Kura Oncology Inc. on 9 of the 11 factors.

Emergent BioSolutions Inc. focuses on the development, manufacture, and commercialization of medical countermeasures that address public health threats. Its products address public health threats primarily chemical, biological, radiological, nuclear, and explosive-related threats, as well as infectious diseases. The companyÂ’s marketed products include BioThrax, an anthrax vaccine; Anthrasil, a polyclonal antibody for the treatment of inhalational anthrax; BAT (Botulism Antitoxin Heptavalent) for the treatment of botulinum disease; vaccinia immune globulin intravenous that addresses adverse events from smallpox vaccination; reactive skin decontamination lotion kit for the removal or neutralization of chemical warfare agents; and Trobigard, an auto-injector device designed for intramuscular self-injection of atropine sulfate and obidoxime chloride. Its investigational stage product candidates include NuThrax, a next generation anthrax vaccine; UV-4B for dengue and influenza infections; GC-072 for Burkholderia pseudomallei; FLU-IG (NP025), a human polyclonal antibody therapeutic being developed to treat seasonal influenza; ZIKA-IG (NP024), a human polyclonal antibody therapeutic being developed as a prophylaxis for Zika infections; and FILOV (NP026), an equine polyclonal antibody therapeutic being developed to treat Ebola infections. In addition, the company provides contract manufacturing services to third-party customers. Emergent BioSolutions, Inc. was founded in 1998 and is headquartered in Gaithersburg, Maryland.

Kura Oncology, Inc., a clinical stage biopharmaceutical company, develops medicines for the treatment of cancers. Its pipeline consists of small molecule product candidates that target cancer. The companyÂ’s lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, lower risk myelodysplastic syndromes, and chronic myelomonocytic leukemia. It also develops KO-947, a small molecule inhibitor of extracellular signal related kinase used for the treatment for patients with tumors that have mutations in, or other dysregulation of, the mitogen-activated protein kinase; and KO-539, a small molecule inhibitor of the menin-mixed lineage leukemia. The company was founded in 2014 and is headquartered in La Jolla, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.